ICON Public Limited (ICLR)
179.12
-0.99 (-0.55%)
At close: Mar 28, 2025, 3:59 PM
178.98
-0.08%
After-hours: Mar 28, 2025, 05:44 PM EDT
ICON Public Limited Revenue Breakdown
| Quarter | Dec 31, 2012 | Sep 30, 2012 | Dec 31, 2011 |
|---|---|---|---|
| Central Laboratory Revenue | 63.49M | 23.98M | 18.67M |
| Central Laboratory Revenue Growth | +164.78% | +28.44% | n/a |
| Clinical Research Revenue | 766.01M | 261.52M | 223.95M |
| Clinical Research Revenue Growth | +192.90% | +16.78% | n/a |
Revenue by Geography
| Quarter | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ireland Revenue | 2.79B | 2.38B | 1.98B | 1.37B | 273.55M | 271.59M | 1.07B | 424.29M | 410.57M | 429.63M | 360.38M | 147.58M | 132.79M |
| Ireland Revenue Growth | +17.50% | +19.78% | +45.29% | +399.33% | +0.72% | -74.53% | +151.29% | +3.34% | -4.44% | +19.22% | +144.19% | +11.14% | n/a |
| Other Countries Revenue | 942.64M | 884.5M | 3.57B | 2.58B | 925.56M | 388.92M | 254.72M | 791.54M | 178.91M | 163.92M | 164.49M | n/a | n/a |
| Other Countries Revenue Growth | +6.57% | -75.26% | +38.50% | +178.86% | +137.99% | +52.69% | -67.82% | +342.43% | +9.14% | -0.35% | n/a | n/a | n/a |
| Rest Of Europe Revenue | 1.56B | 1.57B | n/a | n/a | n/a | 892.5M | 379.88M | n/a | 763.82M | 650.94M | 605.82M | n/a | n/a |
| Rest Of Europe Revenue Growth | -0.89% | n/a | n/a | n/a | n/a | +134.94% | n/a | n/a | +17.34% | +7.45% | n/a | n/a | n/a |
| United States Revenue | 2.99B | 3.28B | n/a | n/a | n/a | n/a | 894.98M | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | -9.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 151.44M | 205.09M | 194.46M | 177.35M | 195.56M | 185.19M | 187.81M | 200.01M | 226.75M | 166.79M | 189.95M | 195.26M | 202.72M | 206.71M | 109.88M | 98.53M | 87.88M | 83.12M | 83.5M | 87.2M | 86.18M | 85.45M | 83.2M | 81.91M | 83.12M | 80.82M | 80.94M | 80.92M | 82.09M | 79.43M | 80.83M | 81.39M | 83.53M | 81.23M | 80.17M | 80.79M | 83.48M | 82.44M | 81.32M | 79.56M |
| Selling, General, and Administrative Revenue Growth | -26.16% | +5.47% | +9.65% | -9.31% | +5.60% | -1.39% | -6.10% | -11.80% | +35.95% | -12.20% | -2.72% | -3.68% | -1.93% | +88.12% | +11.52% | +12.13% | +5.73% | -0.46% | -4.24% | +1.17% | +0.86% | +2.70% | +1.58% | -1.46% | +2.85% | -0.14% | +0.03% | -1.43% | +3.34% | -1.73% | -0.68% | -2.57% | +2.83% | +1.33% | -0.77% | -3.22% | +1.26% | +1.37% | +2.22% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |